Omeros shares oversold, secondary endpoint met, says Maxim Maxim says that while OMS103HP missed its primary endpoint, the drug met its secondary endpoint of pain. The firm adds that pain is directly related to inflammation and the surgical process itself. Maxim finds Omeros shares oversold and said itís a buyer of the stock.
Omeros price target raised to $28 from $20 at Maxim Maxim raised its price target for Omeros shares to $28 citing better than expected pricing for Omidria. The firm believes global sales of the drug could reach north of $400M by 2017 and keeps a Buy rating on Omeros.